We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
OC06.03: Angiogenic factors in the second trimester of pregnancy to detect false positives from the first trimester screening for pre‐eclampsia (STOP‐PRE trial).
- Authors
Mendoza, M.; Bonacina, E.; Garcia‐Manau, P.; Martin, L.; Caamiña, S.; Vives, A.; Quesada, E. Lopez; Ricart, M.; Maroto, A.; Pintado, E.; De Mingo, L.; Armengol‐Alsina, M.; Suy, A.; Carreras, E.
- Abstract
OC06.03: Angiogenic factors in the second trimester of pregnancy to detect false positives from the first trimester screening for pre-eclampsia (STOP-PRE trial) Demonstrate if the sFlt-1/PlGF ratio < 38, measured between 24+0 and 28+0 weeks in women at high risk from the firsttrimester screening for pre-eclampsia (PE), is useful to detect the false positives from the first trimester screening and to stop salicylic acid (ASA) treatment without increasing their rate of preterm PE (requiring delivery at < 37 weeks of gestation). Conclusions Women at high risk for PE in the first trimester screening and sFlt-1/PlGF < 38 at 24+0-28+0 weeks of gestation, can safely stop ASA treatment without increasing the incidence of preterm PE, which could reduce the risk of complications due to unnecessary ASA treatment.
- Publication
Ultrasound in Obstetrics & Gynecology, 2022, Vol 60, p17
- ISSN
0960-7692
- Publication type
Article
- DOI
10.1002/uog.25030